Bain Capital Life Sciences Inv Sells 2,000,000 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00. Following the sale, the insider owned 10,448,158 shares in the company, valued at approximately $293,070,831.90. This represents a 16.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Heartflow Stock Performance

Shares of NASDAQ:HTFL opened at $27.74 on Friday. Heartflow, Inc. has a one year low of $25.38 and a one year high of $41.22. The company has a market cap of $2.36 billion and a P/E ratio of -15.33. The firm has a fifty day moving average price of $30.33.

Institutional Investors Weigh In On Heartflow

Large investors have recently bought and sold shares of the business. TFC Financial Management Inc. bought a new stake in shares of Heartflow in the third quarter worth approximately $40,000. Legal & General Group Plc purchased a new stake in Heartflow in the 3rd quarter worth $59,000. Strs Ohio purchased a new stake in Heartflow during the 4th quarter valued at approximately $99,000. Staley Capital Advisers Inc. bought a new position in shares of Heartflow during the 4th quarter valued at about $204,000. Finally, Connable Office Inc. bought a new position in shares of Heartflow during the 4th quarter valued at approximately $220,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on HTFL shares. JPMorgan Chase & Co. increased their target price on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Canaccord Genuity Group increased their price objective on Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Wells Fargo & Company started coverage on shares of Heartflow in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 target price for the company. Finally, Stifel Nicolaus lifted their price target on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Heartflow currently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.